» Articles » PMID: 10877794

Comparison of Cryptosporidium Parvum Viability and Infectivity Assays Following Ozone Treatment of Oocysts

Overview
Date 2000 Jul 6
PMID 10877794
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Several in vitro surrogates have been developed as convenient, user-friendly alternatives to mouse infectivity assays for determining the viability of Cryptosporidium parvum oocysts. Such viability assays have been used increasingly to determine oocyst inactivation following treatment with chemical, physical, or environmental stresses. Defining the relationship between in vitro viability assays and oocyst infectivity in susceptible hosts is critical for determining the significance of existing oocyst inactivation data for these in vitro assays and their suitability in future studies. In this study, four viability assays were compared with mouse infectivity assays, using neonatal CD-1 mice. Studies were conducted in the United States and United Kingdom using fresh (<1 month) or environmentally aged (3 months at 4 degrees C) oocysts, which were partially inactivated by ozonation before viability and/or infectivity analyses. High levels of variability were noted within and between the viability and infectivity assays in the U.S. and United Kingdom studies despite rigorous control over oocyst conditions and disinfection experiments. Based on the viability analysis of oocyst subsamples from each ozonation experiment, SYTO-59 assays demonstrated minimal change in oocyst viability, whereas 4',6'-diamidino-2-phenylindole-propidium iodide assays, in vitro excystation, and SYTO-9 assays showed a marginal reduction in oocyst viability. In contrast, the neonatal mouse infectivity assay demonstrated significantly higher levels of oocyst inactivation in the U.S. and United Kingdom experiments. These comparisons illustrate that four in vitro viability assays cannot be used to reliably predict oocyst inactivation following treatment with low levels of ozone. Neonatal mouse infectivity assays should continue to be regarded as a "gold standard" until suitable alternative viability surrogates are identified for disinfection studies.

Citing Articles

Parasites in Sewage: Legal Requirements and Diagnostic Tools.

Obuch-Woszczatynska O, Bylinska K, Krzyzowska M, Korzekwa K, Baska P Pathogens. 2025; 14(1).

PMID: 39861047 PMC: 11768300. DOI: 10.3390/pathogens14010086.


Cryptosporidium parvum inactivation from short durations of treatment with ozonated water produced by an electrolytic generation system.

Matsubayashi M, Haraguchi A, Morisaki M, Ikadai H, Teramoto I, Kido Y Parasitol Res. 2024; 123(11):371.

PMID: 39503909 DOI: 10.1007/s00436-024-08390-z.


Comparative Effect of Allicin and Alcoholic Garlic Extract on the Morphology and Infectivity of Oocysts in Chickens.

Abd-ELrahman S, Mohamed S, Mohamed S, El-Khadragy M, Dyab A, Hamad N Animals (Basel). 2022; 12(22).

PMID: 36428412 PMC: 9686627. DOI: 10.3390/ani12223185.


Hastening Progress in Requires Studying Surrogates.

Tucker M, Khan A, Jenkins M, Dubey J, Rosenthal B Microorganisms. 2022; 10(10).

PMID: 36296256 PMC: 9608778. DOI: 10.3390/microorganisms10101977.


Dynamically expressed genes provide candidate viability biomarkers in a model coccidian.

Tucker M, OBrien C, Jenkins M, Rosenthal B PLoS One. 2021; 16(10):e0258157.

PMID: 34597342 PMC: 8486141. DOI: 10.1371/journal.pone.0258157.


References
1.
Rochelle P, Ferguson D, Handojo T, de Leon R, Stewart M, Wolfe R . An assay combining cell culture with reverse transcriptase PCR to detect and determine the infectivity of waterborne Cryptosporidium parvum. Appl Environ Microbiol. 1997; 63(5):2029-37. PMC: 168492. DOI: 10.1128/aem.63.5.2029-2037.1997. View

2.
Arrowood M, Donaldson K . Improved purification methods for calf-derived Cryptosporidium parvum oocysts using discontinuous sucrose and cesium chloride gradients. J Eukaryot Microbiol. 1996; 43(5):89S. DOI: 10.1111/j.1550-7408.1996.tb05015.x. View

3.
Sulaiman I, Xiao L, Yang C, Escalante L, Moore A, Beard C . Differentiating human from animal isolates of Cryptosporidium parvum. Emerg Infect Dis. 1998; 4(4):681-5. PMC: 2640237. DOI: 10.3201/eid0404.980424. View

4.
Widmer G, Orbacz E, Tzipori S . beta-tubulin mRNA as a marker of Cryptosporidium parvum oocyst viability. Appl Environ Microbiol. 1999; 65(4):1584-8. PMC: 91224. DOI: 10.1128/AEM.65.4.1584-1588.1999. View

5.
Pieniazek N, Bornay-Llinares F, Slemenda S, da Silva A, Moura I, Arrowood M . New cryptosporidium genotypes in HIV-infected persons. Emerg Infect Dis. 1999; 5(3):444-9. PMC: 2640774. DOI: 10.3201/eid0503.990318. View